The assay focuses on developing a new therapy, called "Orphan Receptor Bypass Therapy" (ORByT) for addressing Niemann Pick Type C (NPC), a rare neurodegenerative lipidosis. The therapy aims to identify small chemical compounds that can modulate the expression of endogenous "suppressor" proteins and provide treatment for LSD pathogenesis. Rab9 is one such protein whose overexpression can reverse aspects of the NPC phenotype. Is the molecule effective to this assay?